한글목차

골다공증 치료제 동향과 예측

세계 골다공증 치료제 시장은 2024년부터 2030년까지 3.2%의 CAGR로 2030년까지 약 172억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 전 세계적으로 골다공증 발생이 증가하고 노인 인구가 증가함에 따라 골다공증 발생이 증가하고 있습니다. 세계 골다공증 치료제 시장의 미래는 일차성 골다공증 시장과 이차성 골다공증 시장에서 사업 기회가 있어 유망합니다.

골다공증 치료제 시장 인사이트

Lucintel은 골절 위험이 높은 환자의 골다공증 치료에 RANKL 억제제의 채택이 증가함에 따라 RANKL 억제제가 예측 기간 동안 가장 큰 부문을 차지할 것으로 예상하고 있습니다.

고령화 인구의 급격한 증가와 골다공증에 대한 소비자의 인식이 높아짐에 따라 원발성 골다공증은 이 시장에서 큰 비중을 차지할 것으로 보입니다.

북미 지역은 주요 기업의 존재, 골다공증 환자 증가, 브랜드 의약품의 접근성 등으로 인해 예측 기간 동안 가장 큰 지역으로 남을 것으로 보입니다.

이 보고서는 다음과 같은 11가지 주요 질문에 대한 답변을 담고 있습니다:

• Q.1. 시장 부문 중 가장 유망하고 성장성이 높은 기회는 무엇인가?
• Q.2. 어떤 부문이 더 빠른 속도로 성장할 것이며, 그 이유는 무엇인가?
• Q.3. 향후 성장이 가속화될 것으로 예상되는 지역과 그 이유는?
• Q.4. 시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장의 주요 과제와 비지니스 리스크는 무엇인가?
• Q.5. 이 시장에서의 비지니스 리스크와 경쟁 위협은 무엇인가?
• Q.6. 이 시장의 새로운 트렌드와 그 이유는?
• Q.7. 시장에서의 고객 수요 변화에는 어떤 것들이 있는가?
• Q.8. 이 시장의 새로운 발전과 그 발전을 주도하고 있는 기업은?
• Q.9. 이 시장의 주요 기업은? 주요 기업들은 사업 성장을 위해 어떤 전략적 노력을 기울이고 있는가?
• Q.10. 이 시장의 경쟁 제품에는 어떤 것들이 있으며, 소재 및 제품 대체에 따른 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11. 지난 5년간 어떤 M&A가 이루어졌고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 골다공증 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 골다공증 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 약제 종류별 세계 골다공증 치료제 시장
  • 부갑상선호르몬 요법
  • 비스포스포네이트
  • 칼시토닌
  • RANKL 억제제
  • 기타
• 용도별 세계 골다공증 치료제 시장
  • 원발성 골다공증
  • 이차성 골다공증

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 세계의 골다공증 치료제 시장
• 북미의 골다공증 치료제 시장
• 유럽의 골다공증 치료제 시장
• 아시아태평양의 골다공증 치료제 시장
• 기타 지역의 골다공증 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 약제 종류별 세계 골다공증 치료제 시장 성장 기회
  • 용도별 세계 골다공증 치료제 시장 성장 기회
  • 지역별 세계의 골다공증 치료제 시장 성장 기회
• 세계의 골다공증 치료제 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 골다공증 치료제 시장 능력 확대
  • 세계의 골다공증 치료제 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

영문목차

Osteoporosis Drug Trends and Forecast

The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

.

A more than 150-page report is developed to help in your business decisions.

Osteoporosis Drug by Segment

The study includes a forecast for the global osteoporosis drug by drug type, application, and region.

Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others

Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Primary Osteoporosis
• Secondary Osteoporosis

Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Osteoporosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Market Insights

Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.

North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Features of the Global Osteoporosis Drug Market

Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the osteoporosis drug market size?

Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.

Q2. What is the growth forecast for osteoporosis drug market?

Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the osteoporosis drug market?

Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

Q4. What are the major segments for osteoporosis drug market?

Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.

Q5. Who are the key osteoporosis drug market companies?

Answer: Some of the key osteoporosis drug companies are as follows:

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Q6. Which osteoporosis drug market segment will be the largest in future?

Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Osteoporosis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Osteoporosis Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Osteoporosis Drug Market by Drug Type
  • 3.3.1: Parathyroid Hormone Therapy
  • 3.3.2: Bisphosphonates
  • 3.3.3: Calcitonin
  • 3.3.4: RANKL Inhibitors
  • 3.3.5: Others
• 3.4: Global Osteoporosis Drug Market by Application
  • 3.4.1: Primary Osteoporosis
  • 3.4.2: Secondary Osteoporosis

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Osteoporosis Drug Market by Region
• 4.2: North American Osteoporosis Drug Market
  • 4.2.2: North American Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.3: European Osteoporosis Drug Market
  • 4.3.1: European Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.3.2: European Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.4: APAC Osteoporosis Drug Market
  • 4.4.1: APAC Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.4.2: APAC Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.5: ROW Osteoporosis Drug Market
  • 4.5.1: ROW Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.5.2: ROW Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Osteoporosis Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Osteoporosis Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Osteoporosis Drug Market by Region
• 6.2: Emerging Trends in the Global Osteoporosis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Osteoporosis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Osteoporosis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Eli Lily
• 7.3: F. Hoffmann La Roche
• 7.4: Merck
• 7.5: Amgen
• 7.6: Radius Health
• 7.7: Teva Pharmaceutical Industries